Trace amine metabolism in Parkinson's disease: Low circulating levels of octopamine in early disease stages

@article{Dandrea2010TraceAM,
  title={Trace amine metabolism in Parkinson's disease: Low circulating levels of octopamine in early disease stages},
  author={Giovanni D'andrea and Gianpietro Nordera and Gilberto Pizzolato and Andrea Bolner and Davide Colavito and Raffaella Flaibani and Alberta Leon},
  journal={Neuroscience Letters},
  year={2010},
  volume={469},
  pages={348-351}
}

Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson’s Disease Patients

The findings of this pilot cross-sectional study suggest that biochemical anomalies of the aminergic and indolic neurotransmitters occur in PD patients.

Abnormal tyrosine metabolism in chronic cluster headache

It is suggested that anomalies in tyrosine metabolism play a role in the pathogenesis of chronic cluster headache and constitute a predisposing factor for the transformation of the episodic into a chronic form of this primary headache.

The role of tyrosine metabolism in the pathogenesis of chronic migraine

The data support the hypothesis that altered tyrosine metabolism plays an important role in the pathogenesis of CM, and the high plasma levels of TYR may ultimately down-regulate this receptor because of loss of inhibitory presynaptic regulation, therein resulting in uncontrolled neurotransmitter release.

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning

The aim of this review is to present the mechanism of action of L-DOPA with a specific attention to “false neurotransmission,” which could reduce the content of biogenic amines in terminals of monoaminergic neurons, thereby impairing the exocytotic process of monoamines including L- DOPA-induced DA extracellular outflow.

Molecular Sciences L-DOPA in Parkinson’s Disease: Looking at the ”False” Neurotransmitters and Their Meaning

The aim of this review is to present the mechanism of action of L-DOPA with a specific attention to “false neurotransmission,” which could reduce the content of biogenic amines in terminals of monoaminergic neurons, thereby impairing the exocytotic process of monoamines including L- DOPA-induced DA extracellular outflow.

Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective

This mini-review summarizes all catecholamine-related studies to date, providing profound neurochemical evidence on a systemic and cellular level to further emphasize this hypothesis and with emphasis on extracellular vesicles as a novel diagnostic and therapeutic incentive.

Pathogenesis of chronic cluster headache and bouts: role of tryptamine, arginine metabolism and α1-agonists

The low levels of the nitric oxide substrates together with the high levels of noradrenalin and adrenalin suggest an activation of endothelial TAAR1 receptors followed by the release of Nitric oxide in the circulation that may constitute the final step of the physiopathology of cluster crisis.

Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria

E evaluation of the CSF metabolome of a murine model of AKU revealed a significant increase in the abundance of a limited number of metabolites following treatment with nitisinone, and further work is required to understand the significance of these findings and the mechanisms by which the altered metabolite abundances occur.

Neurodegenerative and metabolic disorders, mediated by the trace amines and their receptors

The important role of trace amines and their receptors in the regulation of the dopamine system, in connection with metabolic and neurodegenerative diseases, including Parkinson’s disease, ADHD, schizophrenia, obesity, metabolic syndrome and other pathological conditions, has been shown.

References

SHOWING 1-10 OF 22 REFERENCES

Elevated levels of circulating trace amines in primary headaches

The hypothesis that disorders of biogenic amine metabolism may be a characteristic biochemical trait in primary headache sufferers suggests that they may reflect sympathetic or hypothalamic dysfunction.

Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators

Previous studies showing responses to physiologically relevant concentrations of trace amines are reviewed, along with those showing a reciprocal relationship between trace amine levels and fluctuations in basal monoaminergic tone, and it is hypothesized that the traceAmines function as endogenous neuromodulators of classical monoamine neurotransmitters.

Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

It is shown that RBD patients have a profound impairment of olfactory function, which correlates with the neuropathological staging of Parkinson's disease (stages 1-3) as proposed by Braak.

m‐Octopamine: Normal Occurrence with p‐Octopamine in Mammalian Sympathetic Nerves

A new specific method for the unequivocal identification and quantitative determination in tissue of the six octopamine and synephrine isomers is developed and it is established that m‐ and p‐octopamine are localized within sympathetic nerve endings.

THE EFFECTS OF RESERPINE AND 6‐HYDROXYDOPAMINE ON THE CONCENTRATIONS OF SOME ARYLALKYLAMINES IN RAT BRAIN

The results suggest that p‐ and m‐tyramine may be stored by an intraneuronal reserpine‐sensitive storage mechanism and the tyramines may replace some of the catecholamines from their storage granules and then be released as false transmitters by the nervous impulse.

Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.

It is concluded that it is not the absolute number of serotonin neurons in the grafts, but the relative densities of dopamine and serotonin innervations in the grafted striatum that is the critical factor in determining the long-term effect of foetal tissue graft, beneficial or detrimental, on dyskinesia in grafted Parkinson's disease patients.

Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)

ipathic Parkinson's disease manifests itself in all of its dimensions, which under the influence of the supervening cortical pathology are subject to increasing complexity.

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

Loss of locus coeruleus neurons contributes to motor dysfunction in PD, and MPTP effectively mimics the dopaminergic neuropathology of PD in mice but fails to produce PD-like motor deficits.